December 15, 2014
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
FDA approves two higher dosage strengths of Zubsolv for opioid dependence
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
The FDA has approved two higher dosages of buprenorphine/naloxone sublingual tablets for the maintenance treatment of opioid dependence, according to an Orexo press release.
The new 8.6-mg/2.1-mg dosage of buprenorphine/naloxone (Zubsolv, Orexo) CIII sublingual tablet is expected to launch early 2015; the 11.4 mg/2.9 mg later in 2015.
Existing tablets are available in 5.7-mg/1.4-mg and 1.4-mg/0.36-mg dosages.
The new formulations possess improved taste and faster dissolve time, according to the release.